Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.
Full data show just how big a bust Keynote-598 is, though Bristol is unlikely to abandon hope.
A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.
The company surges 74% though its hints of clinical activity concern just six hep B patients and could include those on placebo.
With no deaths in the treatment arm, Blaze-1 could allow emergency authorisation of the doublet antibody therapy.
Like Lilly, Regeneron reckons its antibodies can be used to prevent Covid-19 infection. Now comes the hard part.
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.